Achilles Therapeutics Plc Stock Today

ACHL Stock  USD 1.03  0.01  0.98%   

Performance

6 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 42

 
High
 
Low
Below Average
Achilles Therapeutics is selling for 1.03 as of the 8th of October 2024. This is a 0.98% increase since the beginning of the trading day. The stock's lowest day price was 0.98. Achilles Therapeutics has about a 42 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Achilles Therapeutics PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of September 2024 and ending today, the 8th of October 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
31st of March 2021
Category
Healthcare
Classification
Health Care
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company was founded in 2016 and is headquartered in London, the United Kingdom. Achilles Therapeutics is traded on NASDAQ Exchange in the United States.. The company has 41.09 M outstanding shares of which 3.85 K shares are presently shorted by private and institutional investors with about 0.09 trading days to cover. More on Achilles Therapeutics PLC

Moving together with Achilles Stock

  0.71BHC Bausch Health CompaniesPairCorr

Moving against Achilles Stock

  0.58PRLD Prelude TherapeuticsPairCorr
  0.4RDY Dr Reddys LaboratoriesPairCorr
  0.39MOLN Molecular Partners Downward RallyPairCorr
  0.37NBIX Neurocrine BiosciencesPairCorr

Achilles Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities13.9 M17 M
Significantly Down
Slightly volatile
Non Current Liabilities TotalM2.1 M
Notably Down
Slightly volatile
Total Assets225.1 M161.5 M
Significantly Up
Slightly volatile
Total Current Assets170.7 M145.6 M
Fairly Up
Slightly volatile
Debt Levels
Achilles Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Achilles Therapeutics' financial leverage. It provides some insight into what part of Achilles Therapeutics' total assets is financed by creditors.
Liquidity
Achilles Therapeutics PLC currently holds 4.62 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Achilles Therapeutics PLC has a current ratio of 11.22, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Achilles Therapeutics' use of debt, we should always consider it together with its cash and equity.

Total Cash From Operating Activities

(51.07 Million)
Achilles Therapeutics PLC (ACHL) is traded on NASDAQ Exchange in USA. It is located in 245 Hammersmith Road, London, United Kingdom, W6 8PW and employs 204 people. Achilles Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 43.82 M. Achilles Therapeutics PLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 41.09 M outstanding shares of which 3.85 K shares are presently shorted by private and institutional investors with about 0.09 trading days to cover. Achilles Therapeutics PLC currently holds about 201.6 M in cash with (48.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Achilles Therapeutics Probability Of Bankruptcy
Ownership Allocation
Achilles Therapeutics holds a total of 41.09 Million outstanding shares. Over half of Achilles Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Achilles Ownership Details

Achilles Stock Institutional Holders

InstituionRecorded OnShares
Citadel Advisors Llc2024-06-30
61.4 K
Xtx Topco Ltd2024-06-30
51.7 K
Two Sigma Advisers, Llc2024-06-30
23.5 K
Virtu Financial Llc2024-06-30
22.8 K
Geode Capital Management, Llc2024-06-30
21.6 K
Two Sigma Investments Llc2024-06-30
21.5 K
Baader Bank Inc2024-06-30
12.4 K
Hrt Financial Llc2024-06-30
10.9 K
Brave Asset Management Inc2024-06-30
10 K
Syncona Portfolio Ltd.2024-06-30
11.1 M
Fcpm Iii Services Bv2024-06-30
2.4 M
View Achilles Therapeutics Diagnostics

Achilles Therapeutics Historical Income Statement

At this time, Achilles Therapeutics' Interest Expense is quite stable compared to the past year. Tax Provision is expected to rise to about 39.2 K this year, although the value of Net Loss is projected to rise to (60.9 M). View More Fundamentals

Achilles Stock Against Markets

Achilles Therapeutics Corporate Management

Sergio QuezadaFounder OfficerProfile
Daniel HoodGeneral SecretaryProfile
Tariq AhmedExecutive PeopleProfile
James TaylorChief OfficerProfile
Julia WilsonHead CommunicationsProfile
Lee SternVice CommunicationsProfile
FMEDSCI MDFounderProfile

Already Invested in Achilles Therapeutics PLC?

The danger of trading Achilles Therapeutics PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Achilles Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Achilles Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Achilles Therapeutics PLC is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Information and Resources on Investing in Achilles Stock

When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.59)
Return On Assets
(0.27)
Return On Equity
(0.44)
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.